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Introduction: Based on previous studies, a preclinical classification for Alzheimer’s disease (AD) has been proposed.
However, 1) specificity of the different neuronal injury (NI) biomarkers has not been studied, 2) subjects with subtle
cognitive impairment but normal NI biomarkers (SCINIB) have not been included in the analyses and 3) progression
to mild cognitive impairment (MCI) or dementia of the AD type (DAT), referred to here as MCI/DAT, varies between
studies. Therefore, we analyzed data from 486 cognitively normal (CN) and 327 DAT subjects in the AD
Neuroimaging Initiative (ADNI)-1/GO/2 cohorts.
Results: In the ADNI-1 cohort (median follow-up of 6 years), 6.3% and 17.0% of the CN subjects developed MCI/DAT
after 3 and 5 years follow-up, respectively. NI biomarker cutoffs [structural magnetic resonance imaging (MRI),
fluorodeoxyglucose positron emission tomography (FDG-PET) and cerebrospinal fluid (CSF) tau] were established in
DAT patients and memory composite scores were calculated in CN subjects in a cross-sectional sample (n = 160). In the
complete longitudinally followed CN ADNI cohort (n = 326, median follow-up of 2 years), CSF and MRI values predicted
an increased conversion to MCI/DAT. Different NI biomarkers showed important disagreements for classifying subjects
as abnormal NI [kappa = (−0.05)-(0.33)] and into AD preclinical groups. SCINIB subjects (5.0%) were more prevalent than
AD preclinical stage 3 subjects (3.4%) and showed a trend for increased progression to MCI/DAT.
Conclusions: Different NI biomarkers lead to different classifications of ADNI subjects, while structural MRI and CSF tau
measures showed the strongest predictive value for progression to MCI/DAT. The newly defined SCINIB category of
ADNI subjects is more prevalent than AD preclinical stage individuals.
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Alzheimer’s disease (AD) is the most common neurode-
generative disease (ND), characterized and diagnosed by
the presence of tau neurofibrillary tangles and amyloid
plaques in the central nervous system [1]. Other neuro-
degenerative and non-degenerative disease pathologies
commonly coexist in patients with dementia of the AD
type (DAT) and community-dwelling subjects [2-5]. The
advent of molecular and neuroimaging AD biomarkers
has enabled researchers to better predict the patholo-
gies underlying DAT [6,7] and to formulate research* Correspondence: trojanow@mail.med.upenn.edu
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unless otherwise stated.diagnostic criteria [8]. These advances have led to the
proposal of a hypothetical AD model [9] for the patho-
logical and biomarker changes to emerge over one or
more decades before the onset of dementia or mild cog-
nitive impairment (MCI) [10-12]. It is thought that amyl-
oid deposition precedes cognitive changes by one or
more decades and cognitive changes appear when mea-
sured amyloid levels approach a plateau. Using this
model, a preclinical staging for AD has been proposed
based on successive and additive presence of Aβ amyloid
deposition (Stage 1), evidence of neuronal injury (NI)
biomarkers (Stage 2) and subtle cognitive impairment
(Stage 3) all of which precedes MCI and DAT. A separate
category for cognitively impaired ADNI subjects with
positive NI biomarkers in the absence of Aβ amyloidLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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(sNAP) has also been proposed [13]. Positron emission
tomography (PET) imaging with Aβ amyloid ligands and
cerebrospinal fluid (CSF) Aβ measurements methods
used for estimation of Aβ amyloid deposition are highly
correlated [14,15], but for the detection of NI due to AD
pathology several other markers are suggested. These
include CSF tau, structural magnetic resonance im-
aging (MRI) and fluorodeoxyglucose PET (FDG-PET). In
addition, classification strategies using neuroimaging bio-
markers are based on assessments of specific or composite
regions of interest (ROI) or pattern analysis methods.
Two studies analyzing different cohorts have described
the baseline and longitudinal outcomes of preclinical
AD staging with a median follow-up of one and 3.9 years
[16,17]. These studies obtained different risk assessments
of conversion from CN to MCI or DAT (referred to here
as MCI/DAT) and used different sets of NI biomarkers.
Although indications are given for the different NI bio-
markers [18], no assessment or comparison of the
different biomarker modalities and processing has been
performed in a single study and this variability might
affect the classification of the subjects into the different
diagnostic categories. There is another potential and un-
explored category of subjects composed of individuals
with subtle cognitive impairment with normal neuronal
injury biomarkers (SCINIB) independent of the presence
or absence of amyloid deposition.
In this study, we 1) compared the agreement of different
NI biomarkers and found important differences in preva-
lence for the different stages of AD, 2) assessed the risk of
conversion to DAT in non-demented ADNI subjects that
was associated with the different biomarkers to select the
best combination of NI biomarkers for the classification of
CN subjects, and 3) evaluated the progression of CN sub-
jects to MCI/DAT based on these selected biomarkers.
Materials and methods
Participants and neuropsychological testing
Data used in the preparation of this article, was down-
loaded from the ADNI database November 1st 2013
[19] (http://adni.loni.ucla.edu/ and Additional file 1:
supplementary material). Diagnosis of MCI and DAT
was established as previously described [20-22] (Additional
file 1: Supplementary Material). We included 486ADNI-1/
GO/2 CN subjects who were divided into two groups
(Figure 1):
a) The first group (Figure 1, blue square) was included
in the longitudinal analysis (n = 326), based on a
follow-up of at least 1 year and presence of baseline
CSF Aβ1–42 or FDG PET measurements (Table 1).
b) The second group of CN subjects (Figure 1, green
square, Additional file 1:Table S2) was composed ofCN subjects without follow-up (n = 100) or without
CSF or FDG PET measures (n = 60). These subjects
were used to estimate the cutoffs that define subtle
cognitive changes for the CN.
327 ADNI-1/GO/2 DAT subjects were included to es-
timate the NI cutoffs for the preclinical AD classification
(Additional file 1: Table S2). A summary composite mem-
ory measure developed by Crane et al. [23] was used to
estimate the presence of subtle cognitive changes.
CSF biomarker collection and analysis
Aβ1–42, t-tau, and p-tau181 were measured using the
multiplex xMAP Luminex platform (Luminex Corp,
Austin, TX) with Innogenetics (INNO-BIA AlzBio3;
Ghent, Belgium; for research use–only reagents) im-
munoassay kit–based reagents (see Additional file 1:
supplementary material) [7,24].
MRI and FDG-PET acquisition and processing
1.5-T MRI and 3-T non-accelerated sagittal volumetric 3D
MPRAGE MRI images were acquired at each performance
site for the ADNI 1 and ADNI-GO/2, respectively (http://
adni.loni.ucla.edu). Only MRIs which passed the quality
control evaluations were included. To estimate hippocam-
pal volumes (HV) measures, cortical grey matter (GM) vol-
umes were processed using Free-surfer software package
version 4.4 and 5.1 image processing framework for the 1.5
and 3-T MRI images, respectively (http://surfer.nmr.mgh.
harvard.edu/) [25,26]. We estimated in an independent
dataset a method to obtain the adjusted HV (aHV; adjusted
for intracranial volume (ICV)) for the MRIs (Additional file
1: supplementary material) (Figure 2a). The SPARE-AD
(Spatial Pattern of Abnormality for Recognition of Early
Alzheimer’s disease) is an index that captures brain atrophy
related to AD [27,28]. FDG-PET data were acquired and
reconstructed with the use of measured-attenuation
correction and the specified reconstruction algorithm
for each scanner type according to a standardized protocol
(http://adni.loni.ucla.edu/). Images were downloaded and
pre-processing using SPM5 by investigators at Banner
Alzheimer’s Institute (http://www.fil.ion.ucl.ac.uk/spm).
We calculated a pattern based summary score, the hypo-
metabolic convergence index (HCI) [29] and an anatom-
ically defined ROI, the posterior cingulate (PC-FDG-PET
with FDG-images using pons as reference region) CMRgl
(cerebral metabolic rate for glucose).
Definition of preclinical AD stages and biomarker and
cognitive cutoffs
Presence of Aβ amyloid deposition consistent with AD
pathology and T-tau and p-tau181 cutoffs were selected
based on cutoffs previously validated in a cohort includ-
ing autopsy confirmed AD subjects [7]. For the MRI and
Table 1 CN ADNI subjects included in the longitudinal study











Progression to - 29 MCI - - 7 MCI -
6 AD 1 AD
Age at baseline
(years)
74.9 (72.0-78.5) 77.0 (73.0-79.2) 0.37 72.6 (69.4-77.1) 83.0 (80.4-84.8) 0.0001 0.0001
Gender (% male) 52.5% 57.1% 0.49 50.9% 75.0% 0.28 0.89
Education (years) 16.0 (14.0-18.0) 16.0 (13.0-18.0) 0.52 16.0 (15.0-18.5) 17.0 (13.8-18.5) 0.86 0.060
APOE ε4 presence 22.5% 31.4% 0.39 29.5% 12.5% 0.44 0.22
ADAS-Cog 9.33 (6.0-12.3) 10.8 (8.6-13.3) 0.047 9.0 (6.0-11) 15.0 (13.5-16.5) 0.0003 0.31
Memory summary
score
0.94 (0.66-1.37) 0.71 (0.44-1.01) 0.006 0.94 (0.55-1.22) 0.22 (0.02-0.42) 0.0004 0.16
Executive summary
score
0.66 (0.29-1.22) 0.40 (0.03-0.77) 0.039 0.82 (0.40-1.44) 0.23 [(−0.15)-0.47] 0.004 0.091
aHV1 812.0 (347.3-1244.5) 586.8 (94.5-1322.6)] 0.25 529.8 (9.0-1085.3) −226.1 [(−419.3)-(6.7)] 0.007 0.015
SPARE-AD −1.44 [(−2.15)-(−0.99)] −1.17 [(−1.74)-(−0.68)] 0.053 −1.32 [(−1.61)-(−1.07)] −0.90 [(−1.04)-(−0.30)] 0.029 0.019
HCI 5.3 (3.3-7.5) 6.0 (3.9-8.7) 0.20 5.5 (3.5-7.7) 7.2 (3.5-13.6) 0.051 0.29
PC-FDG-PET 1.38 (1.29-1.53) 1.29 (1.23-1.43) 0.022 1.45 (1.33-1.51) 1.31 (1.20-1.36) 0.014 0.54
Aβ1–42 (pg/ml) 222.0 (163.5-257.0) 210.0 (144.5-235.0) 0.25 207.7 (158.3-237.3) 147.8 (108.2-205.7) 0.083 0.065
T-tau (pg/ml) 60.0 (47.5-80.8) 71.5 (54.3-95.3) 0.13 56.3 (45.6-81.0) 111.5 (93.7-123.4) 0.032 0.53
P-tau181 (pg/ml) 20.0 (16.0-27.5) 22.0 (17.0-31.5) 0.36 30.0 (21.9-43.1) 35.6 (31.0-44.0) 0.25 <0.0001
aHV = adjusted hippocampal volume.
1Adjusted for intracranial volume.
Median (1st quartile-3rd quartile).
Figure 1 Selection of the cohort and clinical outcomes during follow-up.
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Figure 2 Validation of aHV transformation, cognitive and biomarker cutoffs and progression of ADNI-1 CN subjects. Comparisons of
cross-validated 1.5-T and corresponding 3-T (a). Progression from CN to MCI/DAT in the ADNI-1 cohort (b). Prevalence of the different CN
categories with the use of different neuronal injury biomarkers (c). Conversion of CN subjects to MCI/DAT in adjusted in ADNI-1/GO/2 CN subjects
using aHV (d) (dotted line represents cutpoint of the heaviside function), SPARE-AD (e), t-tau/Aβ1–42 ratio (f) and the CN categories defined by
the combined NI biomarkers (g).
Toledo et al. Acta Neuropathologica Communications 2014, 2:26 Page 4 of 9
http://www.actaneurocomms.org/content/2/1/26FDG-PET NI biomarkers we did not have any available
cutoffs based on a neuropathologically validated sample.
We therefore calculated the cutoffs for the remaining NIbiomarkers based on values that would give 90% sensi-
tivity for DAT (Additional file 1: Table S3, Additional
file 1: Figure S1) [13]. Using this methodology, we could
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score due to its high specificity (only 4.9% of the CN sub-
jects had an abnormal SPARE-AD score). Cutoffs for the
memory score indicative of subtle cognitive changes were
estimated based on the 10th percentile in the CN subjects
not included in the longitudinal analysis [13]. Subjects were
categorized as NI presence if any of the two selected bio-
markers was abnormal. Subjects were classified into the
following categories (Additional file 1: Table S4): 1) Stage 0
[13] (normal Aβ1–42, normal NI biomarker and normal
cognition), 2) Stage 1 (abnormal Aβ1–42, normal NI bio-
markers and normal cognition), 3) Stage 2 (abnormal
Aβ1–42, abnormal NI biomarker and normal cognition),
4) Stage 3 [18] (abnormal Aβ1–42, abnormal NI bio-
marker and abnormal cognition), 5) sNAP [13] (normal
Aβ1–42 and abnormal NI biomarker) and 6) SCINIB
(subtle cognitive impairment with normal NI biomarkers
independent of Aβ1–42) using the different NI biomarkers.
Statistical analysis
For the comparison of baseline clinical, biomarker and
demographic variables Mann–Whitney U and Kruskall-
Wallis tests were applied for the comparison of 2 or 3
groups respectively. For analyses involving an association
with longitudinal outcomes, a Box-Cox transformation
was applied to non-normally distributed variables. Cut-
offs for classification models were selected as described
in previous sections. Agreement between the groups de-
fined by the different NI biomarkers was defined using
the Cohen’s kappa index. The Cox proportional hazard
(PH) model was used to study the progression of CN
subjects to MCI/DAT. This model included age, gender
education and the presence of APOE ε4 allele in
addition to the studied biomarker. Quantitative predic-
tors were normalized and standardized in order to be
able to compare the effect size of the different NI bio-
markers in the PH model. Standardized biomarker
values were set so that positive values would indicate ab-
normal values. The PH assumption was tested analyzing
the correlation between the Schoenfeld residuals and
survival time. In cases where that the assumption was
not meet, a PH with a heaviside function was applied.
No correction for multiple comparisons was applied, be-
cause all of our NI biomarkers were specified a priori
based on the recommended NI biomarkers recom-
mended in the preclinical AD criteria [18] and the ex-
ploratory nature of our analysis. Statistical significance
was set at the p < 0.05 level. All statistical tests were
two-sided.
Results
Description of the cohort
In the total ADNI-1/GO/2 cohort, 43 (8.8%) of the CN
subjects converted to MCI, 10 (2.1%) converted to DAT(8 had an MCI diagnosis before the DAT) and 11 (2.3%)
died (Table 1 and Additional file 1: Table S2). Of the
MCI subjects, 35 (81%) were thought to have a DAT
cognitive impairment profile, whereas 8 (19%) were
thought to have developed MCI due to other etiologies
(Additional file 1: Table S5). All demented patients had a
probable DAT diagnosis. In Figure 2b we plot the sur-
vival plot for the ADNI-1 CN cohort with a median
follow-up of 313 weeks (1st quartile 159 weeks; 3rd quar-
tile: 364 weeks) for comparison with other studies.
86.5% of the ADNI-1 CN subjects had a follow-up of at
least 3 years with a progression to MCI/DAT of 6.3%,
whereas 56.1% had a follow-up of at least 5 years with a
progression to MCI/DAT of 17.0%.
Comparison of groups based on NI biomarkers and
cognitive cutoffs
The different NI biomarkers showed a low agreement,
with Cohen’s kappa index values ranging from −0.05 to
0.33 (values below the diagonal in Table 2) and overall
agreement between the different NI biomarkers ranged
from 45.3% (SPARE-AD and PC-FDG-PET) to 79.0%
(SPARE-AD and T-tau). Therefore, the potential use of
any single biomarker or combinations of NI biomarkers
can lead to important distinctions among the different
categories of non-demented ADNI subjects as summa-
rized in Figure 2c.
Clinical progression based on the different NI biomarkers
and cognitive measures
Due to the absence of any specific recommendations
regarding the use of different combinations of NI bio-
markers to classify the CN subjects, we tested the associ-
ated risk of progression of CN subjects to MCI/DAT
based on the different NI biomarkers in the Cox PH
models (Table 3). Only the MRI and the t-tau/Aβ1–42
values were associated with a higher risk of progression
to MCI/DAT (Figure 2d-f ) while lower baseline memory
measures were the strongest predictors. Finally, we also
selected for further analysis a biomarker from each
modality showing the strongest association with pro-
gression, i.e.t-tau for the CSF and aHV for the neu-
roimaging, and called this model the combined NI
model.
Clinical progression based on the preclinical AD stages
using different combinations of NI biomarkers and clinical
measures
Of the 326 ADNI-1/GO/2 subjects with longitudinal
follow-up, 238 had measurements for the selected NI
biomarkers. Five out of the twelve SCINIB subjects had
abnormal Aβ1–42. The association of the different cat-
egories with progression to MCI/DAT is summarized in
and Table 4 (Figure 2g). Stage 3 was associated with
Table 2 Agreement of biomarker measures for NI and subtle cognitive changes
aHV SPARE-AD HCI PC-FDG-PET T-tau P-tau181
(+) (−) (+) (−) (+) (−) (+) (−) (+) (−)
aHV 66.0% 34.0% 56.4% 43.6% 66.1% 33.9% 60.4% 39.6% 55.75% 44.25%
SPARE-AD 0.06 68.5% 31.5% 50.7% 49.3% 79.0% 21.0% 45.3% 54.7%
HCI 0.05 0.05 64.5% 45.5% 63.6% 36.4% 46.0% 54.0%
PC-FDG-PET 0.33 0.03 0.10 50.8% 49.2% 51.0% 49.0%
T-tau 0.06 0.04 0.11 0.07 63.6% 36.4%
P-tau181 0.15 0.0 −0.01 −0.05 0.31
Numbers below the diagonal represent Cohen’s kappa index. Numbers above the diagonal represent the percentage of subjects that were classified the same way
by the pair of NI biomarkers (+) and the percentage of cases that were classified differently by the pair of NI biomarkers (−).
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showed a trend. Additional file 1: Table S6 lists the re-
sults obtained using neuroimaging-only or CSF-only NI
biomarkers. When subjects were categorized using only
CSF NI biomarker the Stage 3, we found that subjects in
the sNAP or SCINIB category were associated with pro-
gression to MCI/DAT. In none of the models did stage 1
and 2 show an association with faster progression.
Discussion
Our study describes for the first time the unexplored
variability of NI biomarkers among CN subjects, and we
found that CSF tau and structural MRI measures, either
aHV or SPARE-AD, were the strongest predictors of
conversion to MCI/DAT from among a very comprehen-
sive set of NI biomarkers. Selecting the best biomarkers,
we classified the CN subjects and included the SCINIB
category in our analyses since they had not been
analysed in previous study, and we showed a higher
prevalence of the SCINIB category than the AD pre-
clinical stage 3. While only the AD preclinical stage was as-
sociated with increased progression to MCI/DAT, the
SCINIB category showed a trend for progression whichTable 3 Association between NI, tau/Aβ1–42 ratios and
cognitive scores in CN subject with conversion to MCI/DAT





aHV: <=160 weeks 3.11 1.84-5.25 <0.0001
aHV: >160 weeks1 0.92 0.56-1.53 0.76
SPARE-AD 1.46 1.12-1.92 0.006
HCI 1.26 0.84-1.88 0.27
PC-FDG-PET 1.37 0.92-2.03 0.12
T-tau/Aβ1–42 1.60 1.09-2.36 0.016
P-tau/Aβ1–42 1.49 0.52-2.26 0.065
Memory summary score 2.46 1.69-3.56 <0.0001
1For aHV a heaviside function with a time cutpoint of 160 was selected based
on the distribution of the Schoenfeld residuals indicating that after 3 years
group did not differ in risk.
Cox hazards models were adjusted for age, education, gender and APOE ε4
presence. Biomarker values were normalized and standardized for comparison.could become significant with longer follow up of these
subjects.
Two previous studies have described the distribution
of the AD preclinical stages and the progression of CN
to MCI/DAT [16,17] and a third study has described
the neuropsychological changes, but not the diagnostic
changes associated with the preclinical stages of AD
[30]. In the Washington University (WU) study, with a
median follow-up of 3.9 years, the 5-year progression
from CN to a clinical dementia rating of at least 0.5
deemed to be due to AD was 10% [17]. On the other
hand, the Mayo Clinic (MC) population-based study
showed the same progression rate, namely 10%, but with
a follow-up of a single year. In our study, the conversion
from CN to MCI/DAT was 6.3% at 3 years of follow-up
and 17.0% at 5 years of follow-up in the ADNI-1 cohort
(median follow-up of five years). Neither the ADNI nor
the WU cohorts are population-based studies like the
MC cohort and comparisons should be performed to as-
sess baseline differences that explain these findings. In
addition a third study described longitudinal memory
and executive decline in AD preclinical stages 1 and 2
but not in the sNAP category, although conversion to
MCI/DAT was not studied [30].
In our study we included a wide range of standardized
AD biomarker measurements that are used as measures
of NI in the preclinical AD criteria [18]. In addition,
for the MRI and FDG-PET we included two types of
measures, i.e. regions of interest and machine learning
methods. Similarly, two NI measures were available for
the CSF, namely t-tau and p-tau181. The performed ana-
lyses showed that all the NI measures, even those within
the same modality showed an important disagreement
for the classification of subjects according to the consist-
ent absence or presence of NI biomarkers (Table 2 and
Figure 2c). This is not surprising due to the fact that NI
biomarkers track changes in different stages of the dis-
ease and at a different rate [9]. For example, in this study
aHV was only associated with faster progression in the
first years. The measures that showed the highest agree-
ment were CSF t-tau and p-tau181, which showed a high
Table 4 Association between preclinical AD stages and conversion to MCI/DAT
Neuronal injury marker Percentage of subjects
in each category





Combined-NI Stage 0: 31.9% 76 (7) Ref. Ref.
Stage 1: 15.1% 36 (5) 2.6 (0.8-8.6) 0.12
Stage 2: 21.8% 52 (6) 1.8 (0.5-6.3) 0.34
Stage 3: 3.4% 8 (2) 11.3 (1.9-66.9) 0.0072
SNAP: 22.7% 54 (8) 2.4 (0.8-6.9) 0.12
SCINIB: 5.0% 12 (2) 4.9 (0.8-29.1) 0.078
Cox hazards models were adjusted for age, gender and APOE ε4 presence.
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scribed previously [31,32]. In addition, biomarkers with
high sensitivity and specificity, like the SPARE-AD, can-
not be used to categorize subjects using the previous ap-
proaches [13] due to the small overlap between CN and
DAT subjects and therefore cutoffs based on the longitu-
dinal outcomes might be needed for biomarkers with a
high accuracy. Many NI biomarkers might not be disease
specific. This is, for example, the case of MRI HV and
medial temporal lobe measures that can be affected
by different ND and show additive effect from ND
[5,33,34]. This also can be the case of FDG-PET mea-
sures. Nevertheless, p-tau181, which would be expected
to be the most specific NI biomarker, was the one that
was associated with the highest prevalence of sNAP
cases. Interestingly, a recent study reported that in some
cases incident amyloid positivity is preceded by NI posi-
tivity [35]. These results underscore the importance of
standardized studies which include different NI mea-
sures in order to assess the implications of using differ-
ent biomarkers and how this can affect comparability of
different studies.
The WU study used the presence of either abnormal t-
tau or p-tau181 as NI biomarkers and the MC study used
the presence of either abnormal FDG–PET or HCV.
None of the studies assessed the impact of using a wider
panel of different NI measures. From a diagnostic point
of view, specific criteria are needed to define the differ-
ent preclinical AD stages and studies should assess the
different sources of variability for the different NI bio-
markers as well as the specificity that each one offers.
Whereas from a research perspective it might be im-
portant to examine and compare in the same study dif-
ferent types of biomarkers this is not case in clinical
scenarios that require cost effective and reproducible
measures linked to clinical outcomes. Here, we studied
several biomarkers in the ADNI cohort and found that
structural MRI and CSF t-tau were the best predictors
for conversion to MCI/DAT, and therefor they were
used for the combined model. This is in agreement with
previous studies that have shown that either brain atro-
phy [36,37] or CSF biomarkers [30,38,39] are associatedwith an increased risk of progression of CN subjects to
MCI/DAT. Finally, a recent study in a small subset of
ADNI patients has shown that a combination of bio-
markers can predict the conversion from CN subjects to
MCI/DAT [40] and therefore biomarkers combinations
might be able to predict the appearance of cognitive symp-
toms in subjects at risk with higher accuracy than the
preclinical stages and reflecting the different underlying
pathologies in subjects with cognitive impairment [5].
SCINIB is a new category outside the AD hypothetical
model that includes subjects with subtle cognitive
changes who were not previously identified by the array
of NI biomarkers used in AD studies. This category was
more prevalent in the ADNI cohort than the stage 3
group using the combined NI model. The SCINIB group
was composed of a mixture of subjects with normal and
abnormal CSF Aβ1–42 values and this group showed a
trend for increased conversion to MCI/DAT. Previous
studies have not included this group in their main ana-
lyses, because investigators have focused on validating
the preclinical AD stages or subjects with NI measures.
However, this might lead to the impression that the pre-
clinical staging explains most of the conversion of CN
subjects to MCI/DAT. It is not surprising that the SCI-
NIB group might be associated with clinical progression
because it is defined by neuropsychological measures
that are also in part used to establish the clinical diagno-
sis (but this would also apply to the preclinical AD stage
3 groups). This finding underscores the importance of
not excluding SCINIB subjects from studies and charac-
terizing them longitudinally in order to understand their
longitudinal prognosis and potential biomarkers that
identify these subjects.
Conclusion
We confirm that there is increased progression for the
AD preclinical stage 3 and probably SCINIB, but there is
a high classification variability regarding the AD preclin-
ical, sNAP and SCINIB categories based on the selection
of the NI biomarkers that may reflect different aspects
of disease. Therefore specific and standardized criteria
are needed to be able to apply a reproducible and robust
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ition of cutoffs will be needed for biomarker with a high
accuracy. In addition, a large percentage of subjects with
baseline subtle memory changes fell into the SCINIB
category, which needs further study to characterize its
longitudinal outcome and the underlying pathological
changes.
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to MCI/DAT. Cox hazards models were adjusted for age, gender and APOE ε4
presence. Figure S1. Neuronal injury and memory cutoffs. aHV (a), SPARE-AD
(b), HCI (c), FDG-PET ROI score (d) and memory composite score (e) values in
CN and DAT subjects in the samples of subjects used for the estimation of
cutoffs. Dashed line represents the selected cutoff.
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